RxDoctor Payments Data

Vernon Bowman, MD

Family Medicine · Ashdown, ARNPI 1053311068

Payments from drug & device makers

$1,342in general payments, 2019–2025

Across 94 payments — averaging $14.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$481
  • Pfizer$224
  • Mylan Specialty L.p.$125
  • Lilly USA, LLC$87
  • Takeda Pharmaceuticals U.S.A., Inc.$85
  • Astellas Pharma US Inc$56
  • plus $285 from 14 others

What the payments were for

  • Food & beverage$1,342100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,342 in reported general payments places this provider in the 60th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$1,370,563
Medicare patients
1,083
Services billed
23,004

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban220$115,194
JardianceEmpagliflozin45$57,984
JanuviaSitagliptin Phosphate41$35,149
OzempicSemaglutide26$25,054
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$24,237
MounjaroTirzepatide19$19,501
LinzessLinaclotide13$17,288
FarxigaDapagliflozin Propanediol17$15,360
XareltoRivaroxaban12$13,192
MyrbetriqMirabegron16$12,853
Breo ElliptaFluticasone/Vilanterol24$9,696
EntrestoSacubitril/Valsartan27$9,581
Potassium Chloride238$4,805
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$4,769
Gabapentin171$3,601

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$224$117,260231 claims
Boehringer IngelheimJardiance$14$57,98445 claims
MerckJanuvia$42$35,14941 claims
GSKTrelegy Ellipta, Breo Ellipta$15$33,93353 claims
Novo NordiskOzempic$29$25,05426 claims
Lilly USA, LLCMounjaro$87$19,50119 claims
AbbVieLinzess$481$17,28813 claims
Astellas Pharma US IncMyrbetriq$56$12,85316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Ashdown

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →